<DOC>
	<DOCNO>NCT02986373</DOCNO>
	<brief_summary>This open-label extension ( OLE ) study assess efficacy , safety tolerability risankizumab subject psoriatic arthritis ( PsA ) complete dos study drug Week 24 visit Study 1311.5 ( Phase 2 randomize control trial PsA subject , sponsor Boehringer Ingelheim ) .</brief_summary>
	<brief_title>A Study Investigate Safety With Risankizumab Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit Study 1311.5</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Subjects complete dos study drug Week 24 visit Study 1311.5 . Women childbearing potential sexually active , must agree use least one accept method contraception throughout study , include 16 week last dose study drug give . Women childbearing potential must negative urine pregnancy test Baseline ( Week 0/V1 ) . Subjects must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation study specific procedure . Subject judge good health determine Investigator . Female subject pregnant , breastfeed consider become pregnant study participation , include 16 week last dose study drug give . Premature discontinuation study drug Study 1311.5 reason . Use biologic treatment risankizumab since first dose study drug Study 1311.5 . Time elapse &gt; 8 week since Week 24 visit Study 1311.5 . Active systemic infection last 2 week ( exception : common cold ) prior first dose , assessed investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>risankizumab</keyword>
	<keyword>BI655066</keyword>
</DOC>